Imaging angiogenesis of genitourinary tumors

Nature Reviews Urology

Volumn 7, Issue 2, 2010, Pages 69-82

  Zee, Ying Kiat ^a   O'Connor, James P B ^b   Parker, Geoff J M ^b   Jackson, Alan ^b   Clamp, Andrew R ^a   Taylor, M Ben ^a   Clarke, Noel W ^a   Jayson, Gordon C ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBON 11; COMBRETASTATIN A4 PHOSPHATE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; IODINATED CONTRAST MEDIUM; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; OXYGEN 15; PLACEBO; RAZOXANE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; VATALANIB; ANGIOGENESIS INHIBITOR;

ALLERGIC REACTION; BLADDER CANCER; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG RESPONSE; ECHOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGING; KIDNEY CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR VASCULARIZATION; UROGENITAL TRACT TUMOR; ANIMAL; DIAGNOSTIC IMAGING; NEOVASCULARIZATION, PATHOLOGIC; PROCEDURES; UROGENITAL NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANIMALS; DIAGNOSTIC IMAGING; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; UROGENITAL NEOPLASMS;

EID: 77049123664     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.262     Document Type: Review

References (160)

1. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18 (2002).
2. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
3. Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003).
4. Casanovas, O. et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
5. Shim, W. S., Ho, I. A. & Wong, P. E. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol. Cancer Res. 5, 655-665 (2007).
6. Waugh, D. J. & Wilson, C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14, 6735-6741 (2008).
7. Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103-2111 (2007).
8. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
9. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
10. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006). (Pubitemid 44917502)
11. Escudier, B. et al. Sorafenib in advanced clearcell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
12. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
13. Sessa, C. et al. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat. Clin. Pract. Oncol. 5, 378-391 (2008).
14. El-Assal, O. N. et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27, 1554-1562 (1998).
15. Giatromanolaki, A. et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J. Pathol. 179, 80-88 (1996). (Pubitemid 26180086)
16. Nativ, O. et al. Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma. Urology 51, 693-696 (1998).
17. Miles, K. A. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur. J. Radiol. 30, 198-205 (1999).
18. Jayson, G. C. et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl Cancer Inst. 94, 1484-1493 (2002).
19. Rehman, S. & Jayson, G. C. Molecular imaging of antiangiogenic agents. Oncologist 10, 92-103 (2005).
20. O'Connor, J. P. et al. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol. 9, 766-776 (2008).
21. Workman, P. et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J. Natl Cancer Inst. 98, 580-598 (2006).
22. Brooks, P. C. et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822 (1995).
23. Barrett, T. et al. MRI of tumor angiogenesis. J. Magn. Reson. Imaging 26, 235-249 (2007).
24. Idee, J. M. et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 248, 77-88 (2008).
25. Kuo, P. H. et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242, 647-649 (2007).
26. Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 21, 3955-3964 (2003).
27. O'Connor, J. P. et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br. J. Cancer 96, 189-195 (2007).
28. Evelhoch, J. L. Key factors in the acquisition of contrast kinetic data for oncology. J. Magn. Reson. Imaging 10, 254-259 (1999).
29. St Lawrence, K. S. & Lee, T. Y. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J. Cereb. Blood Flow Metab. 18, 1365-1377 (1998).
30. Tofts, P. S. & Kermode, A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn. Reson. Med. 17, 357-367 (1991).
31. Larsson, H. B. et al. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn. Reson. Med. 16, 117-131 (1990).
32. Leach, M. O. et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br. J. Cancer 92, 1599-1610 (2005).
33. Jackson, A. Imaging microvascular structure with contrast enhanced MRI. Br. J. Radiol. 76 (Spec. 2), S159-S173 (2003).
34. Detre, J. A. & Alsop, D. C. Perfusion magnetic resonance imaging with continuous arterial spin labeling: methods and clinical applications in the central nervous system. Eur. J. Radiol. 30, 115-124 (1999).
35. Ye, F. Q. et al. H(2)(15)O PET validation of steadystate arterial spin tagging cerebral blood flow measurements in humans. Magn. Reson. Med. 44, 450-456 (2000).
36. Kimura, H. et al. Perfusion imaging of meningioma by using continuous arterial spinlabeling: comparison with dynamic susceptibilityweighted contrast-enhanced MR images and histopathologic features. AJNR Am. J. Neuroradiol. 27, 85-93 (2006).
37. Boss, A. et al. Magnetic resonance-guided percutaneous radiofrequency ablation of renal cell carcinomas: a pilot clinical study. Invest. Radiol. 40, 583-590 (2005).
38. de Bazelaire, C. et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin. Cancer Res. 14, 5548-5554 (2008).
39. Miettinen, M., Lindenmayer, A. E. & Chaubal, A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens--evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod. Pathol. 7, 82-90 (1994).
40. Witmer, A. N. et al. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J. Histochem. Cytochem. 50, 767-777 (2002).
41. Kan, Z. et al. Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 237, 151-158 (2005). (Pubitemid 41346159)
42. Miles, K. A. Functional computed tomography in oncology. Eur. J. Cancer 38, 2079-2084 (2002).
43. Miles, K. A. et al. Application of CT in the investigation of angiogenesis in oncology. Acad. Radiol. 7, 840-850 (2000).
44. Gupta, N., Price, P. M. & Aboagye, E. O. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur. J. Cancer 38, 2094-2107 (2002).
45. Herbst, R. S. et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol. 20, 3804-3814 (2002).
46. Bacharach, S. L., Libutti, S. K. & Carrasquillo, J. A. Measuring tumor blood flow with H(2)(15)O: practical considerations. Nucl. Med. Biol. 27, 671-676 (2000).
47. Phelps, M. E. et al. Validation of tomographic measurement of cerebral blood volume with C-11-labeled carboxyhemoglobin. J. Nucl. Med. 20, 328-334 (1979).
48. Harvey, C. J. et al. Advances in ultrasound. Clin. Radiol. 57, 157-177 (2002).
49. Cosgrove, D. Angiogenesis imaging--ultrasound. Br. J. Radiol. 76 (Spec. 1), S43-S49 (2003).
50. Krix, M. et al. A multivessel model describing replenishment kinetics of ultrasound contrast agent for quantification of tissue perfusion. Ultrasound Med. Biol. 29, 1421-1430 (2003).
51. Leong-Poi, H. et al. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation 107, 455-460 (2003). (Pubitemid 36158049)
52. Willmann, J. K. et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 246, 508-518 (2008).
53. Amin, M. B. et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am. J. Surg. Pathol. 26, 281-291 (2002).
54. Reuter, V. E. The pathology of renal epithelial neoplasms. Semin. Oncol. 33, 534-543 (2006).
55. Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. Lancet 373, 1119-1132 (2009).
56. Kaelin, W. G. Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. 10, 6290S-6295S (2004).
57. Lebret, T. et al. Percutaneous core biopsy for renal masses: indications, accuracy and results. J. Urol. 178, 1184-1188 (2007).
58. Renshaw, A. A. et al. Accuracy of fine needle aspiration in distinguishing subtypes of renal cell carcinoma. Acta Cytol. 41, 987-994 (1997).
59. Choyke, P. L. et al. Renal cancer: preoperative evaluation with dual-phase three-dimensional MR angiography. Radiology 205, 767-771 (1997).
60. Israel, G. M. & Bosniak, M. A. Follow-up CT of moderately complex cystic lesions of the kidney (Bosniak category IIF). AJR Am. J. Roentgenol. 181, 627-633 (2003).
61. Patard, J. J. Incidental renal tumours. Curr. Opin. Urol. 19, 454-458 (2009).
62. Pallwein, L. et al. Small renal masses: the value of contrast-enhanced colour Doppler imaging. BJU Int. 99, 579-585 (2007).
63. Ascenti, G. et al. Complex cystic renal masses: characterization with contrast-enhanced US. Radiology 243, 158-165 (2007).
64. Park, B. K. et al. Assessment of cystic renal masses based on Bosniak classification: comparison of CT and contrast-enhanced US. Eur. J. Radiol. 61, 310-314 (2007).
65. Eilenberg, S. S. et al. Renal masses: evaluation with gradient-echo Gd-DTPA-enhanced dynamic MR imaging. Radiology 176, 333-338 (1990).
66. Yamashita, Y. et al. Dynamic MRI of small renal cell carcinoma. J. Comput. Assist. Tomogr. 19, 759-765 (1995).
67. Ho, V. B. et al. Renal masses: quantitative assessment of enhancement with dynamic MR imaging. Radiology 224, 695-700 (2002).
68. Hecht, E. M. et al. Renal masses: quantitative analysis of enhancement with signal intensity measurements versus qualitative analysis of enhancement with image subtraction for diagnosing malignancy at MR imaging. Radiology 232, 373-378 (2004).
69. Cheville, J. C. et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 27, 612-624 (2003).
70. Motzer, R. J. & Bukowski, R. M. Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 24, 5601-5608 (2006).
71. Dutcher, J. P. et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN) [abstract]. J. Clin. Oncol. 25 (Suppl. 18), 5033 (2007).
72. Kim, J. K. et al. Differentiation of subtypes of renal cell carcinoma on helical CT scans. AJR Am. J. Roentgenol. 178, 1499-1506 (2002).
73. Ruppert-Kohlmayr, A. J. et al. Differentiation of renal clear cell carcinoma and renal papillary carcinoma using quantitative CT enhancement parameters. AJR Am. J. Roentgenol. 183, 1387-1391 (2004).
74. Sun, M. R. et al. Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes-correlation with pathologic findings. Radiology 250, 793-802 (2009).
75. Pedrosa, I. et al. MR classification of renal masses with pathologic correlation. Eur. Radiol. 18, 365-375 (2008).
76. Lamuraglia, M. et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur. J. Cancer 42, 2472-2479 (2006).
77. Faria, S. C. et al. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am. J. Roentgenol. 189, 378-385 (2007).
78. De Bazelaire, C. et al. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). Acad. Radiol. 12, 347-357 (2005).
79. Flaherty, K. T. et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol. Ther. 7, 496-501 (2008).
80. Hahn, O. M. et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J. Clin. Oncol. 26, 4572-4578 (2008).
81. Clark, J. W. et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11, 5472-5480 (2005).
82. Strumberg, D. et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965-972 (2005).
83. Anderson, H. et al. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br. J. Cancer 89, 262-267 (2003).
84. Solbiati, L., Tonolini, M. & Cova, L. Monitoring RF ablation. Eur. Radiol. 14 (Suppl. 8), P34-P42 (2004).
85. Boss, A. et al. Morphological, contrast-enhanced and spin labeling perfusion imaging for monitoring of relapse after RF ablation of renal cell carcinomas. Eur. Radiol. 16, 1226-1236 (2006).
86. Bono, A. V. et al. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis. 5, 123-127 (2002).
87. Borre, M. et al. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br. J. Cancer 78, 940-944 (1998).
88. Brawer, M. K. et al. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73, 678-687 (1994).
89. Weidner, N. et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143, 401-409 (1993).
90. El-Gohary, Y. M. et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am. J. Clin. Pathol. 127, 572-579 (2007).
91. Du, Z. et al. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin. Med. J. (Engl.) 116, 1936-1939 (2003).
92. Nelson, J. et al. The endothelin axis: emerging role in cancer. Nat. Rev. Cancer 3, 110-116 (2003).
93. Zhang, Y. et al. Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis. Development 135, 775-784 (2008).
94. James, N. D. et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur. Urol. 55, 1112-1123 (2008).
95. Ning, Y. M. et al. Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castrationrefractory prostate cancer (mCRPC) [abstract]. J. Clin. Oncol. 26, 5000 (2008).
96. Schroder, F. H. et al. Screening and prostatecancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328 (2009).
97. Partin, A. W. Does sextant prostate biopsy provide adequate sampling for early detection of prostate cancer? Curr. Urol. Rep. 1, 245 (2000).
98. Frauscher, F. et al. Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet 357, 1849-1850 (2001).
99. Halpern, E. J., Rosenberg, M. & Gomella, L. G. Prostate cancer: contrast-enhanced us for detection. Radiology 219, 219-225 (2001).
100. Seitz, M. et al. Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol. Oncol. doi:10.1016/j.urolonc.2009.03.032
101. Halpern, E. J. et al. Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer 104, 2373-2383 (2005).
102. Roy, C. et al. Contrast enhanced color Doppler endorectal sonography of prostate: efficiency for detecting peripheral zone tumors and role for biopsy procedure. J. Urol. 170, 69-72 (2003).
103. Halpern, E. J. et al. Contrast-enhanced US of the prostate with Sonazoid: comparison with wholemount prostatectomy specimens in 12 patients. Radiology 222, 361-366 (2002).
104. Ito, H. et al. Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound. Br. J. Radiol. 76, 617-624 (2003).
105. Jager, G. J. et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 203, 645-652 (1997).
106. Namimoto, T. et al. The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate. Comput. Med. Imaging Graph. 22, 239-245 (1998).
107. Tanaka, N. et al. Diagnostic usefulness of endorectal magnetic resonance imaging with dynamic contrast-enhancement in patients with localized prostate cancer: mapping studies with biopsy specimens. Int. J. Urol. 6, 593-599 (1999).
108. Franiel, T. et al. Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. Radiology 252, 101-108 (2009).
109. Futterer, J. J. et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 237, 541-549 (2005).
110. Ogura, K. et al. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. Urology 57, 721-726 (2001).
111. Padhani, A. R., Harvey, C. J. & Cosgrove, D. O. Angiogenesis imaging in the management of prostate cancer. Nat. Clin. Pract. Urol. 2, 596-607 (2005).
112. Ling, C. C. et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int. J. Radiat. Oncol. Biol. Phys. 47, 551-560 (2000).
113. van Lin, E. N. et al. IMRT boost dose planning on dominant intraprostatic lesions: gold markerbased three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int. J. Radiat. Oncol. Biol. Phys. 65, 291-303 (2006).
114. Jain, R. K. et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA 95, 10820-10825 (1998).
115. Hayek, O. R. et al. Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity. J. Urol. 162, 1527-1531 (1999).
116. Shabsigh, A. et al. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 36, 201-206 (1998).
117. Eckersley, R. J. et al. Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma. Prostate 51, 256-267 (2002).
118. Buckley, D. L. et al. Prostate cancer: evaluation of vascular characteristics with dynamic contrastenhanced T1-weighted MR imaging--initial experience. Radiology 233, 709-715 (2004).
119. Padhani, A. R. et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 218, 365-374 (2001).
120. Murphy, W. M., Soloway, M. S. & Barrows, G. H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68, 821-828 (1991).
121. Smith, D. M. & Murphy, W. M. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer 73, 1472-1477 (1994).
122. Harvey, C. J. et al. Functional CT imaging of the acute hyperemic response to radiation therapy of the prostate gland: early experience. J. Comput. Assist. Tomogr. 25, 43-49 (2001).
123. Mandeville, H. C. et al. CA4P and external beam radiotherapy in prostate cancer with assessment of effect by DCE-MRI. Clin. Oncol. (R. Coll. Radiol.) 19, S38 (2007).
124. Kershaw, L. E. et al. Late tissue effects following radiotherapy and neoadjuvant hormone therapy of the prostate measured with quantitative magnetic resonance imaging. Radiother. Oncol. 88, 127-134 (2008).
125. Karakunnel, J. et al. Response evaluation by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in a phase II study of cediranib in docetaxel-resistant, castrate resistant prostate cancer (CRPC) [abstract]. Proc. ASCO Genitourinary Cancers Symposium 189 (2008).
126. Kurdziel, K. A. et al. Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. Mol. Imaging Biol. 5, 86-93 (2003).
127. Pound, C. R. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591-1597 (1999).
128. Pollack, A., Zagars, G. K. & Kavadi, V. S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74, 670-678 (1994).
129. Rouviere, O. et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings. Urology 63, 922-927 (2004).
130. Takeda, M. et al. Value of multisectional fast contrast-enhanced MR imaging in patients with elevated PSA levels after radical prostatectomy. Am. J. Roentgenol. 178 (Suppl.), s97 (2002).
131. Nudell, D. M. et al. Imaging for recurrent prostate cancer. Radiol. Clin. North Am. 38, 213-229 (2000).
132. Alonzi, R., Padhani, A. R. & Allen, C. Dynamic contrast enhanced MRI in prostate cancer. Eur. J. Radiol. 63, 335-350 (2007).
133. Dinney, C. P. et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 58, 808-814 (1998).
134. Perrotte, P. et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257-265 (1999).
135. Crew, J. P. Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer. Eur. Urol. 35, 2-8 (1999).
136. Inoue, K. et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin. Cancer Res. 6, 4866-4873 (2000).
137. Theodoropoulos, V. E. et al. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. 95, 425-431 (2005).
138. Knowles, M. A. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J. Urol. 25, 581-593 (2007).
139. Dickinson, A. J. et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br. J. Urol. 74, 762-766 (1994).
140. Bochner, B. H. et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl Cancer Inst. 87, 1603-1612 (1995).
141. Goddard, J. C. et al. Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin. Cancer Res. 9, 2583-2586 (2003).
142. Nicolau, C. et al. Contrast-enhanced ultrasound accuracy in the detection of bladder tumor in patients with hematuria [abstract]. RSNA 94th scientific assembly and annual meeting 575 (2008).
143. Salvaggio, G. et al. Contrast-enhanced ultrasound in the evaluation of bladder neoplasms: preliminary results [abstract]. RSNA 94th scientific assembly and annual meeting 866 (2008).
144. Kim, J. K. et al. Bladder cancer: analysis of multidetector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 231, 725-731 (2004).
145. Jinzaki, M. et al. Detection of bladder tumors with dynamic contrast-enhanced MDCT. AJR Am. J. Roentgenol. 188, 913-918 (2007).
146. Nurmi, M., Katevuo, K. & Puntala, P. Reliability of CT in preoperative evaluation of bladder carcinoma. Scand. J. Urol. Nephrol. 22, 125-128 (1988).
147. Tuncbilek, N. et al. Value of dynamic contrastenhanced MRI and correlation with tumor angiogenesis in bladder cancer. AJR Am. J. Roentgenol. 192, 949-955 (2009).
148. Naish, J. H. et al. Comparison of DCE-MRI and DCE-CT in bladder cancer [abstract]. Proc. Intl Soc. Mag. Reson. Med. 17, 2270 (2009).
149. Barentsz, J. O. et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207, 791-797 (1998).
150. Dobson, M. J. et al. The assessment of irradiated bladder carcinoma using dynamic contrast-enhanced MR imaging. Clin. Radiol. 56, 94-98 (2001).
151. National Cancer Institute Cancer Imaging Program Magnetic Resonance Workshop on Translational Research in Cancer-Tumor Response, Bethesda, MD, November 22-23 [online], http://imaging.cancer.gov/images/Doc uments/14a39040-dad1-46f8-bf88-bae2e7401 ebe/DCE-Recommendationfrom Nov2004NCIWorkshop%282%29.pdf (2004).
152. Canuto, H. C. et al. Characterization of image heterogeneity using 2D Minkowski functionals increases the sensitivity of detection of a targeted MRI contrast agent. Magn. Reson. Med. 61, 1218-1224 (2009).
153. Rose, C. J. et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn. Reson. Med. 62, 488-499 (2009).
154. Buonaccorsi, G. A. et al. Tracer kinetic modeldriven registration for dynamic contrastenhanced MRI time-series data. Magn. Reson. Med. 58, 1010-1019 (2007).
155. Funama, Y. et al. Radiation dose reduction without degradation of low-contrast detectability at abdominal multisection CT with a low-tube voltage technique: phantom study. Radiology 237, 905-910 (2005).
156. Martinsen, A. C. et al. Reduction in dose from CT examinations of liver lesions with a new postprocessing filter: a ROC phantom study. Acta Radiol. 49, 303-309 (2008).
157. Haubner, R. et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781-1785 (2001).
158. Beer, A. J. et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J. Nucl. Med. 46, 1333-1341 (2005).
159. Cooper, C. R., Chay, C. H. & Pienta, K. J. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 4, 191-194 (2002).
160. Rabb, H. et al. Alpha-V/beta-3 and alpha-V/ beta-5 integrin distribution in neoplastic kidney. Am. J. Nephrol. 16, 402-408 (1996).